583 related articles for article (PubMed ID: 8859190)
21. [A study on the relationship between clinicopathological findings of gastric cancer and its biological behavior such as DNA ploidy pattern and immunohistochemical staining of PCNA, laminin, p53 and nm 23].
Shiroko T; Saji S; Kawaguchi Y; Kageyama T; Kunieda K; Umemoto T
Gan To Kagaku Ryoho; 1995 Jun; 22 Suppl 2():118-23. PubMed ID: 7611773
[TBL] [Abstract][Full Text] [Related]
22. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
23. [Significance of COX-2, p53, proliferating cell nuclear antigen and nm23 expressions in gastric cancer and its behavior].
Ji SQ; Hua YW; Zhuang J; Gao Y; Kong Y; Han SL; Shao YF
Ai Zheng; 2002 Jun; 21(6):619-24. PubMed ID: 12452062
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
[TBL] [Abstract][Full Text] [Related]
25. The role of nm23-H1 in the progression of transitional cell bladder cancer.
Chow NH; Liu HS; Chan SH
Clin Cancer Res; 2000 Sep; 6(9):3595-9. PubMed ID: 10999750
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical analysis of estramustine binding protein with particular reference to proliferative activity in human prostatic carcinoma.
Shiina H; Igawa M; Shigeno K; Wada Y; Yoneda T; Shirakawa H; Ishibe T; Shirakawa R; Nagasaki M; Shirane T; Usui T
Prostate; 1997 Jun; 32(1):49-58. PubMed ID: 9207957
[TBL] [Abstract][Full Text] [Related]
27. Comparison of ureteropelvic transitional cell carcinoma with bladder transitional cell carcinoma using an image analyzer.
Shiina H; Igawa M; Urakami S; Shirakawa H; Ishibe T
Urol Int; 1996; 56(3):163-8. PubMed ID: 8860737
[TBL] [Abstract][Full Text] [Related]
28. Expression of nm23-H1 in transitional cell carcinoma of the upper urinary tract.
Cheng HL; Tong YC; Tzai TS; Weng CL; Ho CL; Yang WH; Lin JS; Chow NH
Oncol Rep; 2001; 8(1):193-6. PubMed ID: 11115597
[TBL] [Abstract][Full Text] [Related]
29. p53 overexpression as a prognostic factor for advanced stage bladder cancer.
Kuczyk MA; Bokemeyer C; Serth J; Hervatin C; Oelke M; Höfner K; Tan HK; Jonas U
Eur J Cancer; 1995 Dec; 31A(13-14):2243-7. PubMed ID: 8652250
[TBL] [Abstract][Full Text] [Related]
30. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
[TBL] [Abstract][Full Text] [Related]
31. Ki67, p53, nm23, and DNA cytometry in bladder cancer: potential markers for detection of recurrence?
Feil G; Krause FS; Zumbraegel A; Wechsel HW; Bichler KH
Adv Exp Med Biol; 2003; 539(Pt A):99-109. PubMed ID: 15088899
[No Abstract] [Full Text] [Related]
32. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder.
Gao JP; Uchida T; Wang C; Jiang SX; Matsumoto K; Satoh T; Minei S; Soh S; Kameya T; Baba S
Int J Oncol; 2000 Mar; 16(3):469-75. PubMed ID: 10675477
[TBL] [Abstract][Full Text] [Related]
33. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical analysis of nm23-H1 protein in bladder cancer.
Kuo JY; Chiang H; Chen KK; Chang LS
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):411-7. PubMed ID: 10418173
[TBL] [Abstract][Full Text] [Related]
35. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder.
Serth J; Kuczyk MA; Bokemeyer C; Hervatin C; Nafe R; Tan HK; Jonas U
Br J Cancer; 1995 Jan; 71(1):201-5. PubMed ID: 7819040
[TBL] [Abstract][Full Text] [Related]
36. Expression of p21(waf1/cip1) protein in transitional cell bladder tumours and its prognostic value.
Lipponen P; Aaltomaa S; Eskelinen M; Ala-Opas M; Kosma VM
Eur Urol; 1998 Sep; 34(3):237-43. PubMed ID: 9732201
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical evaluation of nm23-H1 gene product in transitional cell carcinoma of the bladder.
Nakopoulou LL; Constandinides CA; Tzonou A; Lazaris AC; Zervas A; Dimopoulos CA
Histopathology; 1996 May; 28(5):429-35. PubMed ID: 8735718
[TBL] [Abstract][Full Text] [Related]
38. Correlation of nuclear morphometry and immunostaining for p53 and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder.
Ogura K; Fukuzawa S; Habuchi T; Ogawa O; Yoshida O
Int J Urol; 1997 Nov; 4(6):561-6. PubMed ID: 9477184
[TBL] [Abstract][Full Text] [Related]
39. Quantitative analysis of NM23 protein immunoreactivity in renal cell carcinoma using an image analyzer.
Urakami S; Igawa M; Shirakawa H; Shiina H; Kawanishi M
J Urol; 1997 May; 157(5):1928-31. PubMed ID: 9112565
[TBL] [Abstract][Full Text] [Related]
40. [Value of the proliferation status (PCNA) and p53 immunohistochemistry as a prognostic factor for the clinical course of superficial cancer of the urinary bladder].
Kuczyk MA; Serth J; Bokemeyer C; Hervatin C; Oelke M; Oelert F; Höfner K; Jonas U
Urologe A; 1995 Mar; 34(2):146-52. PubMed ID: 7754587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
